Europe Gene Synthesis (Research Use) Market Size to Surpass USD 1,686.44 MN by 2032
The Europe gene synthesis (research use) market size was estimated at USD 385.6 million in 2022 and is expected to surpass around USD 1,686.44 million by 2032 and poised to grow at a compound annual growth rate (CAGR) of 15.9% during the forecast period 2023 to 2032.
Key Takeaways:
Europe Gene Synthesis (Research Use) Market Report Scope
| Report Attribute | Details |
| Market Size in 2023 | USD 446.91 Million |
| Market Size by 2032 | USD 1,686.44 Million |
| Growth Rate From 2023 to 2032 | CAGR of 15.9% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Method, Service, Application, Research phase, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | GenScript; Azenta, Inc. (GENEWIZ); Boster Biological Technology; Twist Bioscience; ProteoGenix, Inc; Biomatik; ProMab; Thermo Fisher Scientific, Inc.; Integrated DNA Technologies, Inc. (Danaher); OriGene Technologies, Inc. |
The growth is mainly driven by various factors including favorable government policies and the development of enzymatic DNA synthetic process. Moreover, decreasing prices of DNA sequencing and synthesis support the market growth.
Gene synthesis is utilized in vaccine development to respond quickly against emerging infections. In addition, gene synthesis has an important role in developing viral vectors used as a delivery system in vaccine development. Viral vectors can deliver antigen genes into host cells, stimulating the immune system against pathogens. Thus, the significance of gene synthesis in vaccine development is projected to drive market growth during the forecast period.
The market has grown substantially over the last few years, owing to the decreasing prices of DNA synthesis and sequencing due to technological advances in human genome sequencing. Moreover, gene synthesis has unique capabilities to make physical copies of genes accurately, easily, and efficiently. The cost of gene synthesis per base pair has decreased drastically from about USD 10 to USD 0.10 over the past decade.
Furthermore, the favorable government policies regarding synthetic biology and several strategic initiatives undertaken by key players drive market growth. For instance, the UK Research Council established The Synthetic Biology for Growth program. The program was focused on research and investment in synthetic biology. The original duration of the program was from 2014 to 2020; however, due to the market's attractiveness, the program investments were extended till 2022.
Major players operating in the market are developing advanced technologies, launching innovative solutions, and partnering with others to gain a competitive advantage. For instance, in May 2023, Twist Bioscience announced the launch of a portfolio of RNA sequencing tools to accelerate biomarker discovery and precision medicine research. Such efforts by key players and the government are expected to fuel the market demand in the coming years.
Method Insights
Based on method, the market is segmented into solid-phase, chip-based, and PCR-based enzyme synthesis. Solid-phase synthesis segment dominated the market in 2022 with a share of 39.3% due to the presence and widespread use of this technique, along with the increasing automation in solid-phase technology, which enhanced the efficiency of DNA synthesis. A rise in the adoption of solid-phase synthesis for biophysical studies also favors segment demand.
The PCR-based enzyme synthesis method is expected to witness the fastest CAGR of 17.9% over the forecast period. The growth of the segment can be attributed to the restraints of the chemical synthesis process, such as producing desired quality DNA for only up to a limited length and the environmental impact of the harsh chemicals used.
Services Insights
In the services segment, the antibody DNA synthesis segment held the largest market share of 62.6% in 2022, owing to an increase in the adoption of gene synthesis in the production of antibodies used for research and the availability of cutting-edge recombinant technology. Furthermore, the increased importance of personalized antibodies and related research for cancer or genetic disorders drives the segment.
The viral DNA synthesis segment is expected to grow at the fastest CAGR of 18.7% during 2023-2032. Gene synthesis enables the construction of viral DNA in the laboratory without needing an existent virus sample. Moreover, the synthesis of viral genomes also assists in recognizing the gene functions and pathogenicity of the organism, allowing for the development of better treatment or disorder prevention options. These applications of viral DNA synthesis services are anticipated to drive the segment.
Application Insights
Based on application, the gene synthesis market is segmented into gene & cell therapy development, vaccine development, and others. The gene & cell therapy development segment held a revenue share of 55.8% in 2022, and it is anticipated to showcase the fastest CAGR over the forecast period. The dominance and growth of the segment can be attributed to several factors, including increasing gene & cell therapy approvals and the growing use of gene synthesis methods for cloning synthetic therapeutic genes in viral vectors. Moreover, the growing adoption of gene & cell therapies and increasing government support are anticipated to drive the segment in the coming years.
Research Phase Insights
Based on research phase, the Europe gene synthesis (research use) market is segmented into preclinical and clinical. The clinical segment accounted for the largest regional market share of 73.7% in 2022. The segment is also projected to display lucrative growth over the forecast period with a CACR of 17.3%. The segment's growth is expected to be driven by the increase in the number of clinical trials for advanced therapy medicinal products. In addition, biomarker discovery and disease modeling are also anticipated to propel segment growth by 2032.
End-use Insights
Based on end-use, the gene synthesis market is segmented into academic & government research institutes, biotechnology & pharmaceutical companies, and contract research organizations (CROs). The academic & government research institutions segment dominated the market with a revenue share of 43.9% in 2022. The segment's dominance is due to expanding research prospects aimed at exploring the use of gene synthesis for studying model organisms. Moreover, enhanced flexibility and automation in gene synthesis facilitated a growing penetration of the technique in research laboratories. Collaborations between industry and academia are expected to boost segment growth over the coming years.
The contract research organization end-use segment is expected to witness the fastest CAGR of 18.3% throughout the forecast period. The growing number of small biotechnology companies and increasing outsourcing trends are anticipated to impact segment growth in the forthcoming years.
Regional Insights
France dominated the Europe research use gene synthesis market with a revenue share of 16.84% in 2022. This dominance can be attributed to several factors, including the presence of key players and numerous initiatives they adopted to strengthen their product and service offerings and enhance their market presence. Moreover, government agencies are supporting the growth and innovation in the market.
For instance, in January 2021, DNA Script and the French Defense Innovation Agency collaborated on the development of new tools for disease diagnosis. The company received USD 1.6 million for this project as part of this collaboration. DNA Script’s novel enzymatic synthesis platform is employed in this project to generate high-fidelity nucleic acids rapidly. Collaborative efforts such as these are expected to fuel market growth over the forecast period.
On the other hand, the Netherlands gene synthesis research use market is projected to grow at the fastest CAGR of 21.1% from 2023 to 2032. The growth is mainly driven by factors such as the presence of a strong network of pharmaceutical and biotechnology companies, supportive government regulations for research, and the presence of various organizations that promote research through funding/grants. For instance, in November 2022, Cradle a Dutch-Swiss biotech startup received funding of USD 5.4 million to speed up its product development. Such investments by market players and government support are expected to drive the market growth over the coming years.
Key Companies & Market Share Insights
Several major players operating in the gene synthesis research use market include Thermo Fisher Scientific, Inc.; GenScript; Twist Bioscience; GENEWIZ; ProMab Biotechnologies, Inc.; and Integrated DNA Technologies, Inc. The market is witnessing growth owing to the numerous strategies key players employ to maintain their industry presence. For instance, in May 2023, GenScript announced the launch of GenTitan Gene Fragments synthesis service to perform gene synthesis at a relatively low cost. In addition, Twist Bioscience announced a collaboration with Astellas Pharma in April 2023 to support antibody discovery for immunotherapies. Some prominent players in the Europe gene synthesis (research use) market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Europe Gene Synthesis (Research Use) market.
By Method
By Service
By Application
By Research Phase
By End-use
By Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Market definitions
1.2. Information Procurement
1.2.1. Market formulation & data visualization
1.2.2. Data validation & publishing
1.3. Research Assumptions
1.4. Research Methodology
1.4.1. Purchased database
1.4.2. Nova one advisor internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis
1.7.1.1. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. Global Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Rising investment in the synthetic biology market
3.3.1.2. Advent of enzymatic DNA synthesis process
3.3.1.3. Technological advancements in the DNA synthesis platforms
3.3.1.4. Declining price of DNA synthesis & sequencing
3.3.2. Market Restraint Analysis
3.3.2.1. Lack of skilled professionals
3.3.2.2. Misuse of gene synthesis
3.4. Industry Analysis Tools
3.4.1. Porter’s Five Forces Analysis
3.4.2. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
3.4.3. COVID-19 Impact Analysis
Chapter 4. Europe Gene Synthesis (Research Use) Market: Method Estimates & Trend Analysis
4.1. Method Movement Analysis & Market Share, 2023 - 2032
4.2. Europe Gene Synthesis (Research Use) Market Estimates & Forecast, By Method (USD Million)
4.3. Solid-Phase Synthesis
4.3.1. Solid Phase Synthesis Market, 2020 - 2032
4.4. Chip Based Synthesis
4.4.1. Chip-Based Synthesis Market, 2020 - 2032
4.5. PCR-based Enzyme Synthesis
4.5.1. PCR-based based Enzyme Synthesis Market, 2020 - 2032
Chapter 5. Europe Gene Synthesis (Research Use) Market: Service Estimates & Trend Analysis
5.1. Service Movement Analysis & Market Share, 2023 - 2032
5.2. Europe Gene Synthesis (Research Use) Market Estimates & Forecast, By Service (USD Million)
5.3. Antibody DNA Synthesis
5.3.1. Antibody DNA Synthesis Market, 2020 - 2032
5.4. Viral DNA Synthesis
5.4.1. Viral DNA Synthesis Market, 2020 - 2032
5.5. Others
5.5.1. Others Market, 2020 - 2032
Chapter 6. Europe Gene Synthesis (Research Use) Market: Application Estimates & Trend Analysis
6.1. Application Movement Analysis & Market Share, 2023 - 2032
6.2. Europe Gene Synthesis (Research Use) Market Estimates & Forecast, By Application (USD Million)
6.3. Gene & Cell Therapy Development
6.3.1. Gene & Cell Therapy Development Market, 2020 - 2032
6.4. Vaccine Development
6.4.1. Vaccine Development Market, 2020 - 2032
6.5. Others
6.5.1. Others Market, 2020 - 2032
Chapter 7. Europe Gene Synthesis (Research Use) Market: Research Phase Estimates & Trend Analysis
7.1. Research Phase Movement Analysis & Market Share, 2023 - 2032
7.2. Europe Gene Synthesis (Research Use) Market Estimates & Forecast, By Research Phase (USD Million)
7.3. Preclinical
7.3.1. Preclinical Market, 2020 - 2032
7.4. Clinical
7.4.1. Clinical Market, 2020 - 2032
Chapter 8. Europe Gene Synthesis (Research Use) Market: End-use Estimates & Trend Analysis
8.1. End-use Movement Analysis & Market Share, 2023 - 2032
8.2. Europe Gene Synthesis (Research Use) Market Estimates & Forecast, By End-use (USD Million)
8.3. Biopharmaceutical & Pharmaceutical Companies
8.3.1. Biopharmaceutical & Pharmaceutical Companies Market, 2020 - 2032
8.4. Academic & Government Research Institutes
8.4.1. Academic & Research Institutes Market, 2020 - 2032
8.5. Contract Research Organizations
8.5.1. Contract Research Organizations Market, 2020 - 2032
Chapter 9. Europe Gene Synthesis (Research Use) Market: Region Estimates & Trend Analysis
9.1. Europe Gene Synthesis (Research Use) Market: Region Outlook
9.2. Europe
9.2.1. Europe Gene Synthesis Market Estimates and Forecast, 2020 - 2032
9.2.2. Germany
9.2.2.1. Key Country Dynamics
9.2.2.2. Target Disease Prevalence
9.2.2.3. Competitive Scenario
9.2.2.4. Germany gene synthesis market estimates and forecast, 2020 - 2032
9.2.3. France
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Competitive Scenario
9.2.3.4. France gene synthesis market estimates and forecast, 2020 - 2032
9.2.4. UK
9.2.4.1. Key Country Dynamics
9.2.4.2. Target Disease Prevalence
9.2.4.3. Competitive Scenario
9.2.4.4. UK gene synthesis market estimates and forecast, 2020 - 2032
9.2.5. Italy
9.2.5.1. Key Country Dynamics
9.2.5.2. Target Disease Prevalence
9.2.5.3. Competitive Scenario
9.2.5.4. Italy gene synthesis market estimates and forecast, 2020 - 2032
9.2.6. Spain
9.2.6.1. Key Country Dynamics
9.2.6.2. Target Disease Prevalence
9.2.6.3. Competitive Scenario
9.2.6.4. Spain gene synthesis market estimates and forecast, 2020 - 2032
9.2.7. Denmark
9.2.7.1. Key Country Dynamics
9.2.7.2. Target Disease Prevalence
9.2.7.3. Competitive Scenario
9.2.7.4. Denmark gene synthesis market estimates and forecast, 2020 - 2032
9.2.8. Sweden
9.2.8.1. Key Country Dynamics
9.2.8.2. Target Disease Prevalence
9.2.8.3. Competitive Scenario
9.2.8.4. Sweden gene synthesis market estimates and forecast, 2020 - 2032
9.2.9. Norway
9.2.9.1. Key Country Dynamics
9.2.9.2. Target Disease Prevalence
9.2.9.3. Competitive Scenario
9.2.9.4. Norway gene synthesis market estimates and forecast, 2020 - 2032
9.2.10. Netherland
9.2.10.1. Key Country Dynamics
9.2.10.2. Target Disease Prevalence
9.2.10.3. Competitive Scenario
9.2.10.4. Netherland gene synthesis market estimates and forecast, 2020 - 2032
9.2.11. Switzerland
9.2.11.1. Key Country Dynamics
9.2.11.2. Target Disease Prevalence
9.2.11.3. Competitive Scenario
9.2.11.4. Switzerland gene synthesis market estimates and forecast, 2020 - 2032
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Share Analysis, 2022
10.4. Company Profiles/Listing
10.4.1. GenScript
10.4.1.1. Overview
10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.1.3. Method Benchmarking
10.4.1.4. Strategic Initiatives
10.4.2. Azenta, Inc. (GENEWIZ)
10.4.2.1. Overview
10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.2.3. Method Benchmarking
10.4.2.4. Strategic Initiatives
10.4.3. Boster Biological Technology
10.4.3.1. Overview
10.4.3.2. Method Benchmarking
10.4.3.3. Strategic Initiatives
10.4.4. Twist Bioscience
10.4.4.1. Overview
10.4.4.2. Method Benchmarking
10.4.4.3. Strategic Initiatives
10.4.5. ProteoGenix, Inc
10.4.5.1. Overview
10.4.5.2. Method Benchmarking
10.4.5.3. Strategic Initiatives
10.4.6. Biomatik.
10.4.6.1. Overview
10.4.6.2. Method Benchmarking
10.4.6.3. Strategic Initiatives
10.4.7. ProMab Biotechnologies, Inc.
10.4.7.1. Overview
10.4.7.2. Method Benchmarking
10.4.7.3. Strategic Initiatives
10.4.8. Thermo Fisher Scientific, Inc
10.4.8.1. Overview
10.4.8.2. Method Benchmarking
10.4.8.3. Strategic Initiatives
10.4.9. Integrated DNA Technologies, Inc. (Danaher)
10.4.9.1. Overview
10.4.9.2. Method Benchmarking
10.4.9.3. Strategic Initiatives
10.4.10. OriGene Technologies, Inc.
10.4.10.1. Overview
10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.10.3. Method Benchmarking
10.4.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers